{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:19:23Z","timestamp":1792343963038,"version":"4.4.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Major depressive disorder (MDD) is more likely to resist to usual treatment when it is associated with post-traumatic stress disorder (PTSD). Capitalizing on the effect of ketamine in both treatment-resistant depression (TRD) and PTSD, we conducted a study in order to assess the efficacy of intranasal (IN) Esketamine in patients having TRD with comorbid PTSD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>In this open-label, single arm, retrospective pilot study, 11 patients were treated with IN Esketamine (56 or 84 mg) with a longitudinal follow-up of 6 months. IN Esketamine was administered twice weekly during the first month, once weekly during the second month, and then once every 1 or 2 weeks. Patients were assessed with Montgomery-\u00c5sberg Depression Rating Scale (MADRS), Patient Health Questionnaire 9 items, Global Assessment of Functioning (GAF), and Clinical Global Impression-Suicide Scale (CGI-SS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 9 women and 2 men (mean age 47.3 \u00b1 11.1 years). The mean (SD) MADRS scores decreased significantly from 38.6 (6.4) at baseline to 18.2 (10.03) after 6 months of IN Esketamine; 7 patients were responders and 3 patients were in remission. The percentage of patients who were moderately to severely suicidal declined from 63.6% at baseline to 27.3% after 1 month of IN Esketamine sessions. No serious adverse reactions were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study reports the outcomes of 11 severely ill patients with comorbid TRD and PTSD after IN Esketamine treatment. Esketamine significantly improved depression symptoms, suggesting that it is likely to be a treatment of choice in this specific population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.865466","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T07:37:58Z","timestamp":1657265878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study"],"prefix":"10.3389","volume":"13","author":[{"given":"Maud","family":"Roth\u00e4rmel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherifa","family":"Benosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"El-Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Berjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Ribayrol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Guillin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Berkovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Moulier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017.","volume":"392","year":"2018","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0193-953X(05)70283-5","article-title":"Definition and epidemiology of treatment-resistant depression.","volume":"19","author":"Fava","year":"1996","journal-title":"Psychiatr Clin North Am."},{"key":"B3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/s0006-3223(03)00088-x","article-title":"Research issues in the study of difficult-to-treat depression.","volume":"53","author":"Rush","year":"2003","journal-title":"Biol Psychiatry."},{"key":"B4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.lpm.2016.02.002","article-title":"[How to define treatment-resistant depression?].","volume":"45","author":"Holtzmann","year":"2016","journal-title":"Presse Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/archpsyc.1995.03950240066012","article-title":"Posttraumatic stress disorder in the national comorbidity survey.","volume":"52","author":"Kessler","year":"1995","journal-title":"Arch Gen Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/00005053-200009000-00006","article-title":"Childhood emotional trauma and chronic posttraumatic stress disorder in adult outpatients with treatment-resistant depression.","volume":"188","author":"Kaplan","year":"2000","journal-title":"J Nerv Ment Dis."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2017.1353383","article-title":"Trauma and PTSD in the WHO world mental health surveys.","volume":"8","author":"Kessler","year":"2017","journal-title":"Eur J Psychotraumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.janxdis.2011.08.003","article-title":"Understanding the relationship between co-occurring PTSD and MDD: symptom severity and affect.","volume":"25","author":"Post","year":"2011","journal-title":"J Anxiety Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/da.22934","article-title":"Risk factors and comorbidity of ICD-11 PTSD and complex PTSD: findings from a trauma-exposed population based sample of adults in the United Kingdom.","volume":"36","author":"Karatzias","year":"2019","journal-title":"Depress Anxiety."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2237-x","article-title":"Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French association for biological psychiatry and neuropsychopharmacology and the fondation FondaMental.","volume":"19","author":"Bennabi","year":"2019","journal-title":"BMC Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jad.2018.06.045","article-title":"The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature.","volume":"242","author":"Johnston","year":"2019","journal-title":"J Affect Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/ijnp\/pyy094","article-title":"Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments.","volume":"22","author":"Kadriu","year":"2019","journal-title":"Int J Neuropsychopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2165\/11633130-000000000-00000","article-title":"Targeting the glutamatergic system to treat major depressive disorder.","volume":"72","author":"Mathews","year":"2012","journal-title":"Drugs."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00767","article-title":"Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies.","volume":"9","author":"Li","year":"2019","journal-title":"Front Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/AAP.0000000000000806","article-title":"Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American society of regional anesthesia and pain medicine, the American academy of pain medicine, and the American society of anesthesiologists.","volume":"43","author":"Schwenk","year":"2018","journal-title":"Reg Anesth Pain Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jad.2021.12.105","article-title":"Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression.","volume":"300","author":"Zheng","year":"2022","journal-title":"J Affect Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.","volume":"106","author":"Zheng","year":"2018","journal-title":"J Psychiatr Res."},{"key":"B19","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s12264-021-00638-3","article-title":"Major depressive disorder: advances in neuroscience research and translational applications. Neurosci Bull.","volume":"37","author":"Li","year":"2021","journal-title":"Erratum Neurosci Bull."},{"key":"B20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1017\/S1092852900016862","article-title":"The role of the glutamatergic system in posttraumatic stress disorder.","volume":"13","author":"Nair","year":"2008","journal-title":"CNS Spectr."},{"key":"B21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry."},{"key":"B22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder.","volume":"178","author":"Feder","year":"2021","journal-title":"Am J Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.07.21260166","article-title":"Modulating amygdala activation to traumatic memories with a single ketamine infusion.","author":"Duek","year":"2021","journal-title":"medRxiv"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11634","article-title":"Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression.","volume":"79","author":"Albott","year":"2018","journal-title":"J Clin Psychiatry."},{"key":"B25","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41386-022-01266-9","article-title":"Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial.","volume":"47","author":"Abdallah","year":"2022","journal-title":"Neuropsychopharmacology."},{"key":"B26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/2045125316631267","article-title":"Ketamine enantiomers in the rapid and sustained antidepressant effects.","volume":"6","author":"Muller","year":"2016","journal-title":"Ther Adv Psychopharmacol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00612","article-title":"Ketamine: 50 years of modulating the mind.","volume":"10","author":"Li","year":"2016","journal-title":"Front Hum Neurosci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/20961790.2017.1285219","article-title":"Metabolism and metabolomics of ketamine: a toxicological approach.","volume":"2","author":"Dinis-Oliveira","year":"2017","journal-title":"Forensic Sci Res."},{"key":"B29","year":"2021","journal-title":"Spravato 28 mg Nasal Spray (Esketamine), Solution. Summary of Product Characteristics."},{"key":"B30","year":"2020","journal-title":"SPRAVATO<sup>\u00ae<\/sup> (Esketamine) Nasal Spray, CIII. Prescribing Information."},{"key":"B31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study.","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry."},{"key":"B32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial.","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2).","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620937899","article-title":"Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review.","volume":"11","author":"Salahudeen","year":"2020","journal-title":"Ther Adv Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/JCP.0000000000001456","article-title":"Switching to intranasal esketamine maintains the antidepressant response to intravenous racemic ketamine administration: a case series of 10 patients.","volume":"41","author":"Banov","year":"2021","journal-title":"J Clin Psychopharmacol."},{"key":"B36","year":"2017","journal-title":"SPRAVATO 28 mg, Solution Pour Pulv\u00e9risation Nasale. R\u00e9sum\u00e9 des Caract\u00e9ristiques Produit."},{"key":"B37","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161645","article-title":"Psychometric validation of the English and French versions of the posttraumatic stress disorder checklist for DSM-5 (PCL-5).","volume":"11","author":"Ashbaugh","year":"2016","journal-title":"PLoS One."},{"key":"B39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jad.2015.03.021","article-title":"Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials.","volume":"180","author":"Hayasaka","year":"2015","journal-title":"J Affect Disord."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1679-x","article-title":"Standardisation framework for the Maudsley staging method for treatment resistance in depression.","volume":"18","author":"Fekadu","year":"2018","journal-title":"BMC Psychiatry."},{"key":"B41","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1).","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1097\/TA.0b013e318160ba1d","article-title":"The correlation between ketamine and posttraumatic stress disorder in burned service members.","volume":"64","author":"McGhee","year":"2008","journal-title":"J Trauma."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fnint.2012.00089","article-title":"Emotion and cognition interactions in PTSD: a review of neurocognitive and neuroimaging studies.","volume":"6","author":"Hayes","year":"2012","journal-title":"Front Integr Neurosci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.neubiorev.2012.11.015","article-title":"Emotional valence modulates brain functional abnormalities in depression: evidence from a meta-analysis of fMRI studies.","volume":"37","author":"Groenewold","year":"2013","journal-title":"Neurosci Biobehav Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/hbm.23085","article-title":"The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study.","volume":"37","author":"Li","year":"2016","journal-title":"Hum Brain Mapp."},{"key":"B46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jad.2015.01.027","article-title":"Presence of psychological distress symptoms associated with onset-related life events in patients with treatment-refractory depression.","volume":"175","author":"Kimura","year":"2015","journal-title":"J Affect Disord."},{"key":"B47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.psychres.2019.01.070","article-title":"Clinical efficacy of trauma-focused psychotherapies in treatment-resistant depression (TRD) in-patients: a randomized, controlled pilot-study.","volume":"273","author":"Minelli","year":"2019","journal-title":"Psychiatry Res."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112342","article-title":"Ketamine reverses the impaired fear memory extinction and accompanied depressive-like behaviors in adolescent mice.","volume":"379","author":"Wei","year":"2020","journal-title":"Behav Brain Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2021.04.004","article-title":"Ketamine treatment upon memory retrieval reduces fear memory in marmoset monkeys.","volume":"50","author":"Philippens","year":"2021","journal-title":"Eur Neuropsychopharmacol."},{"key":"B50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.","volume":"22","author":"Duman","year":"2016","journal-title":"Nat Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.","volume":"329","author":"Li","year":"2010","journal-title":"Science."},{"key":"B52","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pharmthera.2019.02.017","article-title":"Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.","volume":"199","author":"Pham","year":"2019","journal-title":"Pharmacol Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.","volume":"69","author":"Li","year":"2011","journal-title":"Biol Psychiatry."},{"key":"B54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neulet.2016.11.064","article-title":"Glutamate dysregulation and glutamatergic therapeutics for PTSD: evidence from human studies.","volume":"649","author":"Averill","year":"2017","journal-title":"Neurosci Lett."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-017-0829-z","article-title":"Synaptic loss and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic.","volume":"19","author":"Krystal","year":"2017","journal-title":"Curr Psychiatry Rep."},{"key":"B56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cct.2019.04.009","article-title":"Repeated ketamine infusions for antidepressant-resistant PTSD: methods of a multicenter, randomized, placebo-controlled clinical trial.","volume":"81","author":"Abdallah","year":"2019","journal-title":"Contemp Clin Trials."},{"key":"B57","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.biopsych.2018.01.027","article-title":"Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration.","volume":"84","author":"Evans","year":"2018","journal-title":"Biol Psychiatry."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-017-0840-4","article-title":"A network-based neurobiological model of PTSD: evidence from structural and functional neuroimaging studies.","volume":"19","author":"Akiki","year":"2017","journal-title":"Curr Psychiatry Rep."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13651501.2022.2030757","article-title":"Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.","author":"Samalin","year":"2022","journal-title":"Int J Psychiatry Clin Pract."},{"key":"B60","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s00213-005-0094-4","article-title":"Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims.","volume":"182","author":"Sch\u00f6nenberg","year":"2005","journal-title":"Psychopharmacology (Berl)."},{"key":"B61","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy.","volume":"51","author":"Dore","year":"2019","journal-title":"J Psychoactive Drugs."},{"key":"B62","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder.","volume":"179","author":"Grabski","year":"2022","journal-title":"Am J Psychiatry."},{"key":"B63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J Subst Abuse Treat."},{"key":"B64","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000517074","article-title":"Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial.","volume":"90","author":"Wilkinson","year":"2021","journal-title":"Psychother Psychosom."},{"key":"B65","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.encep.2021.08.011","article-title":"[Ketamine augmented psychotherapy (KAP) in mood disorder: user guide].","volume":"48","author":"Bottemanne","year":"2021","journal-title":"Encephale."},{"key":"B66","doi-asserted-by":"publisher","first-page":"84","DOI":"10.24972\/ijts.2014.33.2.84","article-title":"Ketamine psychedelic psychotherapy: focus on its pharmacology, phenomenology, and clinical applications.","volume":"33","author":"Kolp","year":"2014","journal-title":"Int J Transpers Stud."},{"key":"B67","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety.","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.865466\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T07:38:09Z","timestamp":1657265889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.865466\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":67,"alternative-id":["10.3389\/fpsyt.2022.865466"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.865466","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"article-number":"865466"}}